國(guó)際參考定價(jià)是國(guó)際上許多國(guó)家進(jìn)行藥品價(jià)格治理和醫(yī)保支付管理的重要工具之一。歐盟國(guó)家、日本、美國(guó)采用了藥品國(guó)際參考定價(jià)方法。我國(guó)進(jìn)行藥品價(jià)格治理、新藥上市價(jià)格承諾和首發(fā)報(bào)價(jià)參考國(guó)際價(jià)格。建議藥品國(guó)際參考定價(jià)在創(chuàng)新藥先行試點(diǎn)，并逐步向醫(yī)保報(bào)銷藥品推開(kāi)，出臺(tái)實(shí)施細(xì)則、審核監(jiān)督機(jī)制，完善價(jià)格治理綜合體系。

International reference pricing is one of the most important tools in drug price management and payment management. European Union countries, Japan, and the United States have adopted the international reference pricing for drugs. China is implementing drug price management, committing to new drug launch prices, and referencing external prices for initial pricing. It is suggested that international reference pricing for drugs be piloted in innovative drugs and gradually extended to drugs reimbursed by medical insurance. Implementation rules, audit and supervision mechanisms should be introduced to improve the comprehensive system of price governance.

R954